Browse
Submit Data
Databases
API
Help

Dataset Information

24 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Current highlights in lung cancer in 2021.

ABSTRACT:

SUBMITTER: Lim KHJ

PROVIDER: S-EPMC8379292 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group.

Project description:Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.

| S-EPMC8381132 | biostudies-literature

American Heart Association EPI|Lifestyle Scientific Sessions: 2021 Meeting Highlights.

Project description: Not available

| S-EPMC9075080 | biostudies-literature

[Highlights of PAPR Inhibitors in Small Cell Lung Cancer].

Project description:Small cell lung cancer (SCLC), characterized by early metastasis, relapse, relapse and resistance and poor prognosis, still faces difficulties in treatment. Recently, Immunotherapy is a novel treatment for SCLC, researchers are also eager to achieve a breakthrough in targeted treatment of SCLC. Genomic instability of SCLC and sensitivity to cytotoxic chemotherapy, therefore, poly ADP-ribose polymerase (PARP) inhibitors targeting DNA repair related pathways have become a hotspot in the research of SCLC targeted therapy. Studies on PARP inhibitors in SCLC have been conducted in combination with other therapeutic strategies, including the treatment of recurrent SCLC and first-line treatment,as well as maintenance treatment after induction. These studies also explored the predictive markers of PARP inhibitors in SCLC. Although the current results of PARP inhibitors in SCLC are limited, and the predictive markers are also inconsistent, we also see that PARP inhibitors could be a breakthroughfor precision medicine of SCLC.?.

| S-EPMC7519958 | biostudies-literature

ERS International Congress 2021: highlights from the Respiratory Intensive Care Assembly.

Project description:Early Career Members of Assembly 2 (Respiratory Intensive Care) attended the European Respiratory Society International Congress through a virtual platform in 2021. Sessions of interest to our assembly members included symposia on the implications of acute respiratory distress syndrome phenotyping on diagnosis and treatment, safe applications of noninvasive ventilation in hypoxaemic respiratory failure, and new developments in mechanical ventilation and weaning, and a guidelines session on applying high-flow therapy in acute respiratory failure. These sessions are summarised in this article.

| S-EPMC9124870 | biostudies-literature

Highlights from the Current Issue – Audiovisual Summary

Project description: Not available

| S-EPMC3541924 | biostudies-literature

Highlights From the Current Issue – Audiovisual Summary

Project description: Not available

| S-EPMC8804610 | biostudies-literature

Highlights From the Current Issue – Audiovisual Summary

Project description: Not available

| S-EPMC8091425 | biostudies-literature

Highlights From the Current Issue – Audiovisual Summary

Project description: Not available

| S-EPMC7528882 | biostudies-literature

Highlights From the Current Issue – Audiovisual Summary

Project description: Not available

| S-EPMC8014626 | biostudies-literature

American Society of Clinical Oncology 2021 Annual Meeting Highlights for Radiation Oncologists.

Project description:The annual meeting of the American Society of Clinical Oncology is the largest multidisciplinary oncology-focused conference in the world. With more than 4900 total abstracts in 2021 alone, it is difficult for individuals to evaluate all the results. This article presents a review of 32 selected abstracts across all disease sites, focusing on those of greatest relevance to radiation oncologists.

| S-EPMC8767256 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data